# EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)

> **NCT00270790** · PHASE2 · COMPLETED · sponsor: **Mohan Suntharalingam** · enrollment: 21 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Amifostine
- **DRUG:** Carboplatin
- **DRUG:** Taxol
- **DEVICE:** Radiotherapy

## Key facts

- **NCT ID:** NCT00270790
- **Lead sponsor:** Mohan Suntharalingam
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2005-12
- **Final completion:** 2009-02
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270790, "EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00270790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*